Skip to Main Content

Paper Details

A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.
Sci Transl Med
22
2022
Author NameAffiliation
Pavlos MsaouelUniversity of Texas MD Anderson Cancer Center
Pavlos MsaouelDavid H. Koch Center for Applied Research of Genitourinary Cancers, University of Texas MD Anderson Cancer Center
Pavlos MsaouelUniversity of Texas MD Anderson Cancer Center
Alda L TamUniversity of Texas MD Anderson Cancer Center
  • 1 - 4

Datasets

Release 1.2